Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
476 documents

  • ValĂ©rian Reithinger. Assurance qualitĂ© des traitements par hadronthĂ©rapie carbone par imagerie de particules promptes chargĂ©es. JournĂ©e de la Recherche 2016, FacultĂ© de MĂ©decine Lyon-Est, Mar 2016, Lyon, France. ⟨hal-01438834⟩
  • B. Huisman, Jean Michel LĂ©tang, E. Testa, D. Sarrut. Accelerated Prompt Gamma estimation for clinical Proton Therapy simulations. International Conference on Translational Research in Radio-Oncology | Physics for Health in Europe (ICTR-PHE 2016), Feb 2016, Genève, Switzerland. . ⟨hal-01276369⟩
  • Jochen Krimmer, Denis Dauvergne, Etienne Testa. A beam hodoscope for ion therapy monitoring by means of secondary radiations. Wilhelm and Else Heraeus-Seminar Semiconductor detectors in astronomy, medicine, particle physics and photon science, Feb 2016, Bad Honnef, Germany. ⟨hal-01457896⟩
  • Cyrus Chargari, Karyn A. Goodman, Ibrahima Diallo, Jean-Baptiste Guy, ChloĂ© Rancoule, et al.. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35 (2), pp.277-288. ⟨10.1007/s10555-016-9616-2⟩. ⟨hal-01404955⟩
  • Nathalie Bonnin, Emma Armandy, Julien Carras, Sylvain Ferrandon, Priscillia Battiston-Montagne, et al.. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget, 2016, 7 (28), pp.44023-44038. ⟨10.18632/oncotarget.9829⟩. ⟨hal-01376219⟩
  • ChloĂ© Rancoule, Nicolas MagnĂ©, Alexis Vallard, Jean-Baptiste Guy, Claire Rodriguez-Lafrasse, et al.. Nanoparticles in radiation oncology: From bench-side to bedside. Cancer Letters, 2016, 375 (2), pp.256-262. ⟨10.1016/j.canlet.2016.03.011⟩. ⟨hal-01376249⟩
  • Sylvain Ferrandon, Badia El Hamdani, Sophie Gazzo, Priscillia Battiston-Montagne, Michael Beuve, et al.. Carbon ions Versus Îł-Irradiation: The Telomeric Effect in Cancer Cells. Jacobs Journal of Radiation Oncology, 2016, 3 (3), pp.031. ⟨hal-01450160⟩
  • Brent Huisman, Jean Michel LĂ©tang, Etienne Testa, David Sarrut. Accelerated prompt gamma estimation for clinical proton therapy simulations. Physics in Medicine and Biology, 2016, 61 (21), pp.7725-7743. ⟨10.1088/0031-9155/61/21/7725⟩. ⟨hal-01391649⟩
  • B. MĂ©ry, A. Vallard, S. Espenel, N. Badie, M. Thiermant, et al.. Cancer de prostate des sujets âgĂ©s : place et rĂ´le de l’évaluation gĂ©riatrique. Progrès en Urologie, 2016, 26 (9), pp.524 - 531. ⟨10.1016/j.purol.2016.07.002⟩. ⟨hal-01376268⟩
  • Julien Smeets, Frauke Roellinghoff, Guillaume Janssens, Irene Perali, Andrea Celani, et al.. Experimental comparison of Knife-edge and Multi-Parallel slit collimators for Prompt gamma imaging of Proton Pencil Beams. Frontiers in Oncology, 2016, 6, pp.156. ⟨10.3389/fonc.2016.00156⟩. ⟨hal-01457574⟩

Powered by HAL logo